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A 38-year-old woman with a smoking history of 15 pack-years was admitted to the hospital with severe dyspnea, 
cough, and weight loss. Computed tomography (CT) scan 
of the chest revealed a paravertebral mass in the right upper 
lobe with a massive pleural thickening surrounding the whole 
right lung, pleural effusion in the right pleural cavity, medias-
tinal adenopathy, and small metastatic lesions in the left lung 
(Fig. 1A). Thoracoscopy followed by drainage of pleural fluid 
led to a pathological diagnosis of papillary lung adenocarci-
noma. Molecular profiling showed ROS1 rearrangement in 
fluorescence in situ hybridization assay (commercial certified 
laboratory service with in-house developed probes against 
ROS1 gene). The patient received four cycles of palliative 
chemotherapy consisting of pemetrexed and cisplatin, which 
resulted in disease stabilization. After a short treatment-free 
interval, she experienced clinical and radiological signs of 
progression and was commenced on crizotinib, an anaplastic 
lymphoma kinase (ALK), ROS1, and MET inhibitor, 250 mg 
twice daily. Subsequent chest CT showed a partial response of 
the thoracic lesions (Fig. 1B), accompanied by a marked symp-
tomatic improvement. Six months after initiation of crizotinib, 
she presented with fatigue, dysarthria, and depression, with 
episodes of catatonia. Contrast-enhanced CT showed no brain 
lesions and continued response in the chest. Brain magnetic 
resonance imaging (MRI) revealed miliary dissemination in 
the form of small (2–7 mm) high signal nodules in T2 and pro-
ton density–weighted images, involving almost exclusively 
the grey matter: cerebral cortex, basal ganglia, and thalamus 
(Fig. 2A and B). Some of the metastases showed restricted 
diffusion in DWI images and ADC maps. Diagnosis of brain 
dissemination was confirmed by Gd-DTPA–enhanced MRI, 
which revealed enhancing lesions on T1-weighted images 
(Fig. 3A). Crizotinib was temporarily stopped, patient received 
whole-brain radiotherapy (WBRT) at a dose of 30 Gy in 10 
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FIGURE 1.  Contrast-enhanced computed tomography of 
the chest—mediastinal window. Neoplastic pleural thicken-
ing of the right lung. A, Initial chest computed tomography 
examination. B, After 4 months of crizotinib treatment. 
C, After 13 months of crizotinib treatment.
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fractions, and crizotinib was restarted. WBRT resulted in a 
marked symptomatic improvement, with resolution of depres-
sion and only a slight dysarthria. T1-weighted Gd-DTPA 
contrast-enhanced MRI performed 4 months after WBRT 
showed continued partial response in the brain (Fig. 3B), and 
CT showed continued partial response in the chest (Fig. 1C).
DISCUSSION
Approximately 10% to 25% of patients with lung can-
cer are initially diagnosed with brain metastases and another 
40% to 50% will develop brain dissemination during the 
course of their disease.1 Miliary dissemination presenting as 
multiple punctate tumor nodules with a perivascular distri-
bution is a rare manifestation of brain metastases.2 Very few 
cases of miliary brain metastases have been reported, usu-
ally detected by MRI examinations; CT is less useful in such 
cases. This form of dissemination arises most often from lung 
adenocarcinoma.2
ROS1 gene rearrangement is found in 1% to 2% of lung 
adenocarcinomas and tumors harboring this feature are par-
ticularly sensitive to crizotinib.3 In the present case, a patient 
with lung adenocarcinoma harboring ROS1 rearrangement 
developed miliary brain metastases involving almost exclu-
sively grey matter while on crizotinib therapy. Brain imaging 
was not performed before commencement of crizotinib ther-
apy due to lack of symptoms of CNS involvement; therefore, 
we cannot exclude pre-existing brain dissemination. However, 
neurological and psychiatric symptomatic deterioration of the 
patient was striking, accompanied by miliary brain metastases 
in the brain, whereas a continued response in the chest was 
observed. Taken together, clinical and radiological findings 
of this patient indicated exclusive progression in the CNS. 
To our knowledge, this is the first report of such a radiologi-
cal image of an ROS1-rearranged lung cancer. Progressions 
in the brain with continued response in the extracranial sites 
have been described for ALK-rearranged adenocarcinoma 
patients treated with crizotinib.4 This phenomenon is likely 
due to a low penetration of crizotinib through the blood–
brain barrier possibly resulting in insufficient inhibition of 
ROS1 protein. Next-generation ROS1 inhibitors with presum-
ably better CNS penetration are currently evaluated in clini-
cal trials (ASP3026, AP26113; clinicaltrials.gov identifiers 
NCT01284192 and NCT01449461, respectively).5 It is hoped 
FIGURE 2.  Miliary brain metastases 
developed after 6 months of com-
mencement of crizotinib treatment—
small high-intensity lesions in the 
cerebral cortex and basal ganglia. A, 
proton density–weighted MRI image. 
B, T2-weighted MRI image, trans-
verse plane. MRI, magnetic resonance 
imaging.
FIGURE 3.  T1-weighted Gd-DTPA 
contrast-enhanced magnetic resonance 
images, sagittal plane. Miliary brain 
metastases developed after 6 months of 
commencement of crizotinib treatment 
(A) with partial regression after palliative 
brain radiotherapy and further 4 months 
of crizotinib treatment (B). Gd-DTPA, 
gadopentetate dimeglumine. 
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that these agents will be associated with a better CNS control 
of ROS1-rearranged lung cancer.
In summary, present description may indicate that cen-
tral nervous system constitutes a sanctuary site for ROS1-
rearranged lung cancer, similar to ALK-driven lung cancer.
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